- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00458263
Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature (ISS)
January 1, 2013 updated by: Rabin Medical Center
One Arm, Open Study to Assess Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
One arm, open, prospective, intervention study to assess biochemical markers of growth response to Growth Hormone treatment in 20 Children, aged 3-9 years old, with idiopathic short stature.
All participants will be treated with Growth Hormone during the first year of the study (and then in accordance with the local ethic requirement, to supply drug which is not approved for the indication used in the study, for additional 3 years) and then will be followed up for the next 3 years.
The impact of Growth Hormone therapy on clinical laboratory parameters that are indicative of the growth response will be assessed by collecting blood and urine samples during the 4 years study period.
The primary endpoints are measurements of height and growth velocity during the year of Growth Hormone treatment, the height at the beginning of puberty and final height.
Secondary endpoints are psychological parameters, assessed by questionnaires.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
One arm, open prospective intervention study to assess biochemical markers of growth response to Growth Hormone treatment in 20 children, aged 3-9 years old, with idiopathic short stature.
Objectives:
- To determine axiological and biochemical markers for growth response
- To assess the period of time necessary to determine the parameters which will differentiate between responders and non-responders
Inclusion criteria:
- Ages 3 to <9 years
- Short stature with height >2.25 Standard Deviation below the mean
- Prepubertal (Tanner stage I) at commencement of trial
- Peak Growth Hormone above 10ng/ml in at least one provocative test for Growth Hormone secretion
- Signing Informed consent forms
Exclusion criteria:
- Intra Uterine Growth Retardation
- Growth retardation associated with malignancy, severe chronic disease, genetic syndromes and endocrine disorders
- Diabetes
- Treatment with any medical product which may interfere with Growth Hormone effects
Methods:
- All participants will be treated with Growth Hormone during the first year of the study (and then in accordance with the local ethic requirement, to supply drug which is not approved for the indication used in the study, for additional 3 years) and then will be followed up for the next 3 years.
- The impact of Growth Hormone therapy on clinical laboratory parameters that are indicative of the growth response will be assessed by collecting blood and urine samples during the 4 years study period.Samples will be test for biochemical markers of bone formation and resorption
- The primary endpoints are measurements of height and growth velocity during the year of Growth Hormone treatment, the height at the beginning of puberty and final height. Secondary endpoints are psychological parameters, assessed by questionnaires.
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Petach Tikva, Israel, 49202
- Schneider Children Medical Center of Israel
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 years to 9 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ages 3 to <9 years
- Short stature with height >2.25 Standard Deviation below the mean
- Prepubertal (Tanner stage I) at commencement of trial
- Peak Growth Hormone above 10ng/ml in at least one provocative test for Growth Hormone secretion
- Signing informed consent forms
Exclusion Criteria:
- Intra Uterine Growth Retardation
- Growth retardation associated with malignancy, severe chronic disease, genetic syndromes and endocrine disorders
- Diabetes
- Treatment with any medical product which may interfere with Growth Hormone
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single arm
|
daily Sub Cutaneous injections
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Height
Time Frame: every 4 months
|
every 4 months
|
Growth velocity
Time Frame: every 4 months
|
every 4 months
|
Height at beginning of puberty
Time Frame: At the biginning of puberty
|
At the biginning of puberty
|
Final height
Time Frame: When acheiving final height
|
When acheiving final height
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Psychological parameters
Time Frame: once a year
|
once a year
|
HbA1c and IGF-1
Time Frame: at baseline. after 3 months and than every 6 months
|
at baseline. after 3 months and than every 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Moshe Phillip, Prof, MD, Schneider Children Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2006
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
May 1, 2011
Study Registration Dates
First Submitted
April 8, 2007
First Submitted That Met QC Criteria
April 8, 2007
First Posted (Estimate)
April 10, 2007
Study Record Updates
Last Update Posted (Estimate)
January 3, 2013
Last Update Submitted That Met QC Criteria
January 1, 2013
Last Verified
October 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- rmc003515ctil
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Short Stature
-
Belgian Study Group for Pediatric EndocrinologyActive, not recruitingIdiopathic Short StatureBelgium
-
Dong-A ST Co., Ltd.CompletedIdiopathic Short Stature
-
Merck KGaA, Darmstadt, GermanyCompletedIdiopathic Short StatureKorea, Republic of
-
PfizerCompletedIdiopathic Short StatureUnited States
-
BioMarin PharmaceuticalNot yet recruitingIdiopathic Short Stature
-
Novo Nordisk A/SRecruitingIdiopathic Short StatureUnited States
-
University of Erlangen-Nürnberg Medical SchoolCompletedIdiopathic Short StatureGermany
-
Children's Hospital Medical Center, CincinnatiCompleted
-
Rabin Medical CenterPfizerCompleted
-
BioMarin PharmaceuticalRecruitingIdiopathic Short StatureUnited States
Clinical Trials on Somatotropin growth hormone recombinant human
-
University of MilanEli Lilly and CompanyUnknownGrowth Hormone Deficiency, Dwarfism | PseudohypoparathyroidismItaly
-
University of PennsylvaniaBaylor Health Care SystemCompletedTraumatic Brain InjuryUnited States
-
Ache Laboratorios Farmaceuticos S.A.Unknown
-
Columbia UniversityTercicaTerminatedGrowth Hormone DeficiencyUnited States
-
CinnagenCompleted
-
Massachusetts General HospitalGenentech, Inc.CompletedAnorexia Nervosa | Osteoporosis | Osteopenia | Eating DisordersUnited States
-
Center for Human ReproductionUnknownFemale Infertility Due to Diminished Ovarian ReserveUnited States
-
Versartis Inc.Completed
-
Beni-Suef UniversityRecruiting
-
Postgraduate Institute of Medical Education and...UnknownChronic Myelogenous Leukemia | Short StatureIndia